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Abstract The PRECISE study used convection enhanced
delivery (CED) to infuse IL13-PE38QQR in patients with
recurrent glioblastoma multiforme (GBM) and compared
survival to Gliadel Wafers (GW). The objectives of this
retrospective evaluation were to assess: (1) catheter posi-
tioning in relation to imaging features and (2) to examine
the potential impact of catheter positioning, overall cathe-
ter placement and imaging features on long term clinical
outcome in the PRECISE study. Catheter positioning and
overall catheter placement were scored and used as a sur-
rogate of adequate placement. Imaging studies obtained on
day 43 and day 71 after resection were each retrospectively
reviewed. Catheter positioning scores, catheter overall
placement scores, local tumor control and imaging change
scores were reviewed and correlated using Generalized
Linear Mixed Models. Cox PH regression analysis was
used to examine whether these imaging based variables
predicted overall survival (OS) and progression free sur-
vival (PFS) after adjusting for age and KPS. Of 180
patients in the CED group, 20 patients did not undergo
gross total resection. Of the remaining 160 patients only
53% of patients had fully conforming catheters in respect
to overall placement and 51% had adequate catheter
positioning scores. Better catheter positioning scores were
not correlated with local tumor control (P = 0.61) or
imaging change score (P = 0.86). OS and PFS were not
correlated with catheter positioning score (OS: P = 0.53;
PFS: P = 0.72 respectively), overall placement score (OS:
P = 0.55; PFS: P = 0.35) or imaging changes on day 43
MRI (P = 0.88). Catheter positioning scores and overall
catheter placement scores were not associated with clinical
outcome in this large prospective trial.
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Recurrent glioblastoma multiforme (GBM) has a dismal
prognosis with a median survival of 6 months despite
multi-modality treatment strategies. The introduction of
temozolamide led to prolonged survival of newly diag-
nosed patients with GBM after radiation and surgical
resection to 15 months [1] but therapeutic options for
recurrent GBM are limited. Gliadel wafers (GW) are
currently the only Food and Drug Administration (FDA)
approved local treatment for recurrent GBM. The restric-
tive blood brain barrier (BBB) remains a tremendous
challenge for the development of systemically delivered
therapeutics. Ongoing studies are currently investigating
the role of regional delivery systems for these patients
including convection enhanced delivery (CED) combined
with targeted therapy such as cintredekin-besudotox (CB)
and TP-38, a recombinant protein targeting the epidermal
growth factor receptor [2, 3]. CB, also referred to as IL13-
PE38QQR, has been tested in prior phase I studies using
CED as delivery methodology. CB, a recombinant cyto-
toxin composed of the human interleukin -13 (IL-13) and
a truncated form of the Pseudomonas aeruginosa Exotoxin
A, has been shown to be highly toxic to cells expressing
the IL-13 receptor [4, 5]. Pseudomonas Exotoxin A kills
mammalian cells by catalyzing irreversible ADP-ribosyl-
ation and inactivation of the elongation factor 2 necessary
for protein synthesis. Human GBMs express high levels of
the IL-13 receptor in comparison to normal brain and
therefore this genetically engineered drug should be highly
speciﬁc to tumor cells [6, 7]. Investigations to assess if
CED can successfully distribute IL13-PE38QQR demon-
strated that co-infusion of IL13-PE38QQR with
123I-
labeled human serum albumin (HAS) in patients with
GBM led under ideal circumstances to adequate tissue
distribution of the drug [8]. The authors also identiﬁed that
proximity to subarachnoid space and placement close to an
ependymal surface has a signiﬁcant detrimental inﬂuence
on the drug delivery. Speciﬁc catheter positioning place-
ment guidelines were therefore proposed based on these
ﬁndings with an emphasis on adequate depth from brain
surface, sulcus or resection cavity as well as distance from
ependymal and pial surfaces. Timing of catheter place-
ment is also important for the accuracy of the positioning.
Edema, ﬂuid shifts and re-expansion after surgical resec-
tion of the tumor limits the use of pre-surgical MRIs for
catheter placement planning. Therefore most neurosur-
geons using CED as delivery method will plan a second
procedure for catheter implantation based on post resec-
tion images. Prior phase I studies found that accurate
catheter positioning based on these guidelines seem to be a
critical factor to improve OS assuming that accurately
positioned catheters result in better drug distribution.
These studies also proved that CB could be infused safely
via CED in patients after tumor resection [9]. The imaging
changes seen on MRIs of patients treated with CB via
CED are summarized by Parney et al. [10] and a speciﬁc
scoring system has been established. It is thought that
higher grades of imaging changes are due to a necrotic and
inﬂammatory processes involving also normal brain. The
underlying mechanism is not well understood but higher
concentration of the drug could potentially lead to non-
targeted uptake of CB and therefore also harm normal
tissue. However, others have shown that the development
of new T2/FLAIR signal abnormalities after delivery of
CB via CED is an indication of successful drug delivery
using concurrent infusion of CB and
123I-labeled HSA in
combination with SPECT analysis [11]. The encouraging
results from prior phase I studies led to the design of the
multicenter phase III trial. The PRECISE study is the
largest surgically based randomized clinical trial to date
using CED in comparison to other local therapy in
recurrent GBM. No survival advantage in patients treated
with IL13-PE38QQR compared to GW was identiﬁed with
a median survival of 36.4 weeks for CB and 35.3 weeks
for GW (P = 0.476) with hazard ratio of 0.89 (95% CI:
0.67–1.18). Although progression free survival (PFS) was
not an endpoint centrally reviewed in this trial, the study
reported an improved PFS of 17.7 weeks for CB over a
PFS of 11.4 weeks for GW (P = 0.008). To further elu-
cidate which factors are essential to respond to this type of
therapy, we assessed MRIs of all patients receiving IL13-
PE38QQR in respect to catheter positioning scores, overall
catheter placement scores, local recurrence of disease,
imaging changes associated with the therapy as well as the
effect of these variables on clinical outcome.
Materials and methods
Cintredekin besudotox (CB)
The sequence encoding IL13-PE38QQR was created by
Dr. Debinski and further developed by Dr. Raj K. Puri,
M.D., Ph.D. in the department of Tumor Vaccines and
Biotechnology Branch, Center for Biologics Evaluation
and Research, FDA. The sequence was incorporated into a
plasmid at Advanced BioScience Laboratories (Kensing-
ton, MD) and later at Diosynth (Morrisville, MC). Esch-
erichia coli bacteria were transformed with a plasmid
containing the CB sequence, protein synthesis was
induced and expanded. CB was puriﬁed as described prior
under current good manufacturing practices [6]. CB was
infused at a concentration of 0.5 lg/ml at a total rate of
0.750 ml/h for 96 h after catheter placement was
conﬁrmed.
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The PRECISE study is an international, multicenter study
across the U.S, Canada, Europe and Israel. Adult patients
with recurrent supratentorial GBM, histologically con-
ﬁrmed at initial presentation, were eligible for the trial. The
patients had to be surgical candidates with an intent of gross
total resection (GTR), deﬁned as more than 95% of the total
volume of the enhancing lesion. Other inclusion criteria
consisted of Karnofsky performance score C70 as well as
prior radiation therapy completed C4 weeks prior to study
entry. Patients who had multifocal disease, subependymal
or leptomeningeal spread, evidence of tumor crossing the
midline, or who showed signs of signiﬁcant increased
intracranial pressure, had uncontrolled seizures, or required
emergent palliative treatment were excluded. Survival was
deﬁned as the number of days from the date of randomi-
zation to the date of death or last known alive date. PFS was
deﬁned as the number of days from the date of randomi-
zation to the date of tumor progression as determined by the
investigator. For detail see Kunwar et al. [12].
Imaging overview
All patients underwent pre-resection contrast MRI imaging
(with and without gadolinium) within 7 days prior to sur-
gery. Within 72 h after resection all patients underwent an
MRI scan (slices \3 mm without spacing) to assess the
extent of resection. These images were also used to plan for
guidelines-compliant catheter trajectories. Based upon this
planning MRI scan, on the day of catheter placement, two
to four catheters were stereotactically placed by the treating
neurosurgeon. To conﬁrm proper catheter positioning, a
non-contrast CT scan using slices B3 mm without spacing
was performed prior to start the IL13-PE38QQR infusion.
Follow-up contrast MR images were obtained at day 43
and day 71 post infusion and consistently collected for
central review for all patients.
Catheter planning and placement
The surgical planning procedure for the infusion catheters
was performed using the MRI scan obtained within 72 h of
resection. The images were reviewed on the planning
computer station or the surgical navigation station. Virtual
trajectories were generated based upon the guidelines
outlined in Table 1. Each trajectory was reviewed in
Probe’s Eye View in order to ensure adherence to the
placement guidelines. Barium impregnated infusion cath-
eters (Vygon, Norristown, PA, USA), not speciﬁcally
designed for CED, were inserted in the operating room
under local or general anesthesia. Using a sterile frameless
or frame based stereotactic placement technique, two to
four catheters were inserted into the brain parenchyma
based on the surgical plan. For frameless insertion, the
guideline was to use rigidly mounted holding devices
rather than free-hand approaches in order to minimize
deviations of actual versus planned catheter trajectories.
The stylets from the catheters were slowly removed under
constant irrigation so that the vacuum in the catheter would
draw ﬂuid down into the catheter and reduce the amount of
air in the infusion system. Catheters were then tunneled
beneath the scalp to reduce the risk of infection. Each
catheter was connected to a separate micro infusion pump
(MEDEX 3500 or equivalent). Placement was conﬁrmed
on CT imaging within 24 h of placement. The technique
for placement was however not centrally mandated and
was left to the discretion of each investigator. Infusion was
started within 24 h after catheter placement. All members
of the clinical team involved in the study received on-site
and off-site training to gain basic proﬁciency and comfort
level in using CED for the PRECISE Trial (BrainLAB AG,
Feldkirchen, Germany). Investigators were not permitted to
enroll a second patient until their ﬁrst patient’s plan and
catheter placements were reviewed and deemed acceptable.
In all cases, near real-time, but post-treatment, analysis of
catheter planning and placement was performed and feed-
back was provided to the surgeon. Major deviations from
the guidelines or from the catheter plan resulted in a
requirement for retraining prior to enrollment of another
patient.
A separate post-resection procedure for placement of
catheters was chosen to improve the accuracy of catheter
positioning by avoiding the effects of postoperative edema
as well as brain shift and re-expansion on catheter posi-
tioning that can occur with placement at the time of
resection.
Central case review of catheter placement
A central case review procedure to assess catheter place-
ment was established in order to optimize clinical trial
management and to improve interpretability of patient
outcome. For this review BrainLAB collected anonymous
data for each patient (post-resection/catheter planning
MRI, post-catheter placement CT scan) in DICOM format
at every site after treatment was completed. BrainLAB
imported all available data to the iPlan
 Flow planning and
simulation software (BrainLAB AG, Feldkirchen, Ger-
many). The planning functionality was used to add a virtual
trajectory for every catheter depicted on the CT scan. To
visualize these trajectories on all available images, CT and
MRI data were overlaid using the image fusion function-
ality in the iPlan
 Flow planning and simulation software,
which is described in more detail elsewhere [8, 13, 14].
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123Three CED experienced neurosurgeons (MV, MW and
SK) reviewed all images for each individual patient inde-
pendently after the study was completed. Each catheter was
measured and rated for compliance with the placement
guidelines for catheter position geometry (catheter posi-
tioning score) and overall catheter placement for each
patient (overall catheter placement score). Tables 1 and 2
summarize the catheter positioning scoring scheme based
on study guidelines. The overall placement with respect of
localization of the catheters to T2/FLAIR signal abnor-
mality, resection cavity as well to other catheters was
assessed in the central review process as well. Tables 3
and 4 summarize the overall catheter placement scoring
system.
Retrospective imaging analysis
Images obtained on day 43 and day 71 after resection
during the PRECISE trial were each retrospectively
reviewed at the University of California, San Francisco
(UCSF) for patients treated with IL13-PE38QQR via CED
with the objectives to: (1) assess catheter placement in
relation to imaging features and (2) examine the potential
impact of catheter positioning score, overall catheter
placement score and imaging features on long term clinical
outcome. A trained UCSF neuroradiologist (BL), who was
blinded to the clinical outcome, conﬁrmed the extent of
tumor resection for each patient as well as progression or
recurrence of disease on either day 43 or day 71 MRI.
Imaging change scores were assessed for each catheter as
outlined in Table 5 [10]. Local tumor control was deﬁned
as absence of tumor recurrence or progression within 1 cm
radius of the trajectory length of the catheter. Local tumor
control was assessed for each catheter. Progression was
deﬁned as existing tumor that was enlarging over interval
MRI scans. Recurrence was deﬁned as new nodular or
suspicious enhancement at day 43 or 71 after GTR was
conﬁrmed on immediate postoperative MRI.
Statistical analyses
Patients with extent of resection less than 95% were
excluded from the analysis to ensure that the statistical
analyses were based on the intended population. To explore
whether the catheter positioning score predicted local
tumor control or imaging change scores on day 43 and day
71 MRIs, we employed the extended versions of logistic
regression model and proportional odds model. These types
of statistical models belong to the class of Generalized
Linear Mixed Models (GLMM), which takes into proper
consideration the correlation arising from multiple cathe-
ters (two to four) in each of the patients. Similarly, a
Table 2 Scoring system for assessment of catheter positioning
Score Deﬁnition
0 Poor: criterion A not fulﬁlled (regardless of other criteria)
1 Fair: criteria A and either B or C fulﬁlled
2 Good: all three criteria fulﬁlled
Table 3 Criteria for overall catheter placement
Criterion Deﬁnition
I Target includes areas of T2/FLAIR abnormalities and
largest adjacent area of white matter
II Catheter tips are C20 mm apart from each other
III If any residual, solid contrast-enhancing disease is present
the catheter tip is positioned adjacent but not into it
Table 4 Scoring system for overall catheter placement
Score Deﬁnition
F = fully conforming Criteria I, II and III (if applicable) fulﬁlled
P = partially
conforming
Only one criteria fulﬁlled or criteria I and II
fulﬁlled with criteria III failed
(if applicable)
N = non-conforming No criteria fulﬁlled
Table 5 Imaging change score
Imaging change
score
MRI changes
a
I Hyperintense signal abnormality on FLAIR related
to catheter tract or tip only. No new contrast-
enhancement
II Mild contrast-enhancement (\1.0 cm or linear)
related to catheter tract or tip
III Moderate contrast-enhancement (1.0–3.0 cm)
related to catheter tract or tip
IV Extensive contrast-enhancement ([3.0 cm) related
to catheter tract or tip, with or without central
hypointensity
a Contrast-enhancing lesions diameter include the central hypoin-
tensity, if present
Table 1 Criteria for catheter positioning
Criterion Deﬁnition
A Depth C25 mm from brain surface or any deep sulcus, or
from resection cavity wall if placed through the resection
cavity
B Catheter tip C5 mm from any pial surfaces
C Catheter tip C10 mm from the resection cavity walls or
any ependymal surfaces
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if imaging change score was associated with local tumor
control. Both catheter positioning score and imaging
change score were treated as categorical variables when
included as covariates in the model. These analyses were
performed using STATA version 10.0 [15]. The Survival
package in R version 2.7.1 was utilized to evaluate whether
any imaging-based variable predicted long term survival
[16]. For these analyses, two or more catheters optimally
positioned (i.e. catheter positioning score 2; see Tables 1
and 2) were used as the categorical cut-off. For overall
catheter placement score, patients assessed as ‘‘non-con-
forming’’ were collapsed with the ‘‘partially conforming’’
category due to limited number in the former category.
Similarly, two or more catheters with imaging change score
graded II or above (see Table 5) were used as the criterion
for the purpose of dichotomization. For the local tumor
control variable, patients were categorized into either
achieving local tumor control in all catheters or having at
least one local catheter failure. To assess whether catheter
positioning score or overall catheter placement predicted
long term clinical outcome, the Cox proportional hazards
(Cox PH) model was used to allow for the adjustment of
the known prognostic markers of age and KPS. Further, to
examine the impact of day 43 and day 71 imaging variables
(i.e. local tumor control and imaging change score) on
clinical outcomes, we used a landmark analysis approach
based on Cox PH model. For example, to evaluate whether
local tumor control on day 43 MRIs predicted OS or PFS,
all patients alive with known local tumor control status on
day 43 were included in the analysis. Survival was counted
as number of days from the date that day 43 MRI was
performed until date of death due to any cause and Cox PH
model was then used to adjust for factors including age and
KPS. Adjustments for multiple comparisons was made by
choosing P values of \0.01 to indicate statistical
signiﬁcance.
Results
Distribution of catheter scores and imaging grading
scores in the CB treated population
Among 183 patients in the CED ITT population, the extent
of resection could not be evaluated in three patients.
Twenty patients had signiﬁcant residual disease and were
excluded from this analysis. This differs from the analysis
by Sampson et al. [17], who included all patients treated in
the PRECISE trial with CB. The analysis was based on 160
patients. Of note, only 50 patients had no evidence of any
residual disease deﬁned as contrast enhancing lesion after
surgery per USCF review. Seventy-ﬁve patients (47%)
treated with IL13-PE38QQR via CED had three catheters
placed, 63 (39%) had four catheters, and only 16 patients
had two catheters. With respect to the overall catheter
placement score, 83 patients (54%) were judged to fulﬁll
all of the criteria as outlined in Tables 3 and 4 (i.e. fully
conforming), while 65 patients (40%) only partially ful-
ﬁlled the criteria and 5 patients (3%) did not fulﬁll any.
Table 6 summarizes the distribution of each imaging
based variable on the catheter level along with the patient
number for which the assessment of each variable was
available. The catheter scores were available for 154
patients with 509 catheters placed in total. Out of these
catheters, 258 (51%) were determined as fulﬁlling all
catheter positioning criteria and were assigned an optimal
score of 2, 59 catheters (12%) were scored 1 and 192
catheters (38%) scored 0. At the patient level (data not
shown), 84 out of 154 patients (55%) had 2 or more
catheters with an optimal score of 2. Local tumor control
assessment for each catheter was available for 119 and 102
patients on day 43 and day 71, respectively. Local tumor
control was achieved in 310/384 catheters (81%) on day 43
MRI and 267/329 catheters (81%) on day 71 MRI achieved
local tumor control per UCSF designation. Furthermore,
Table 6 Distribution of catheter positioning score, local tumor con-
trol and imaging change score
Variable Number of catheters (%)
Catheter positioning score (# pts = 154)
0 192 (38)
1 59 (12)
2 258 (51)
Local tumor control
Day 43 (# pts = 119)
No 74 (19)
Yes 310 (81)
Day 71 (# pts = 102)
No 62 (19)
Yes 267 (81)
Image change score
Day 43 (# pts = 15)
0 40 (11)
1 92 (26)
2 178 (50)
3 37 (10)
4 6 (2)
Day 71 (# pts = 99)
0 38 (13)
1 73 (25)
2 139 (47)
3 36 (12)
4 7 (2)
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control on both day 43 and day 71, among which 94% had
the same assessments on both days (one-sided 95% lower
conﬁdence limit = 91%). At the patient level (data not
shown), 82 patients (69%) on day 43 and 69 patients (68%)
on day 71 achieved local tumor control on all catheters
placed. Imaging change score due to CB via CED was
graded according to guidelines outlined in Table 5 [10].
Imaging change scores on both day 43 and day 71 were
evaluated for 271 catheters, among which 80% had the
same imaging change scores on both days (one-sided 95%
lower conﬁdence limit = 76%). The majority of catheters
had low to moderate imaging grading scores: 87% and 85%
scored II or below on day 43 and day 71, respectively. The
distribution of imaging change score found in our study
resembles that previously reported by Kunwar et al. [9]
based on earlier phase I studies using CB at a similar
concentration.
Correlative analysis of catheter scores, local tumor
control and imaging changes
A prior study of patients treated with CB via CED sug-
gested that the development of new T2/FLAIR signal
abnormality is associated with drug distribution [11]. We
therefore used the imaging change score as a surrogate for
drug distribution in this imaging analysis. We hypothesized
that better catheter scores may be correlated with better
tumor control and higher imaging grading scores. Table 7
summarizes the correlative analysis of catheter positioning
score, local tumor control and imaging change score based
on day 43 and day 71 MRI data. We found that, contrary to
our premise, catheter positioning score was neither pre-
dictive of local tumor control (P = 0.61 and P = 0.66 on
day 43 and day 71 respectively) nor predictive of imaging
change score (P = 0.86 and P = 0.014 on day 43 and day
71 respectively). In addition, imaging change score was not
correlated with local tumor control either on day 43
(P = 0.2) or day 71 (P = 0.24).
Effect of catheter positioning score, overall catheter
placement score and imaging change score on clinical
outcome
The composite analysis of prior phase I trials by Kunwar
et al. [9] demonstrated that patients with two or more
catheters positioned per guidelines (n = 24) had an
improved median survival of 55.6 weeks (95% CI, 21.0–
45.9) compared to 37.4 weeks (95% CI, 21.0–45.9) for
patients with fewer than two catheters optimally positioned
(n = 19). In this analysis, we set out to determine if these
results based on phase I studies can be replicated and to
examine whether the additional imaging variables we
collected may be predictive of clinical outcome. Table 8
summarizes the individual effect of the overall placement
score, catheter positioning score, imaging grading score
and local tumor control on clinical outcome (OS and PFS)
based on the Cox PH model adjusting for age and KPS. In
this larger, multicenter study we failed to demonstrate an
effect of the catheter positioning score on OS (P = 0.53) or
PFS (P = 0.72). Patients with two or more catheters
optimally positioned (n = 84) had a median OS survival of
39.9 weeks (95% CI, 32.6–52.4), compared to a median
OS of 45.6 weeks (95% CI, 36.4–65.0) among those with
Table 7 Correlative analysis of relationship among catheter positioning score, local tumor control and imaging change score on day 43 and day
71 MRI evaluation
Outcome Predictor Day 43 Day 71
# Pts # Catheters OR (95% C.I.) P-value # Pts # Catheters OR (05% C.I.) P-value
Tumor control
a Catheter score 116 371 0.61 101 321 0.66
2 vs. 0/1 0.79 (0.32–1.94) 1.22 (0.50–2.99)
Tumor control
b Imaging change score 115 352 0.20 98 287 0.24
1 vs. 0 0.13 (0.01–3.04) 0.09 (0–10.4)
2 vs. 0 0.05 (0–1.15) 0.02 (0–2.66)
3/4 vs. 0 0.09 (0–2.68) 0.01 (0–2.96)
Imaging change score
c Catheter score 112 341 0.86 99 289 0.014
2 vs. 0/1 0.97 (0.73–1.29) 1.47 (1.08–2.00)
a,b OR represents the odds of achieving local tumor control comparing higher scores vs. lower scores of the corresponding predictors
c Imaging change scores 3 and 4 are combined due to limited number of catheters scored 4
OR (based on proportional odds model) represents the odds of achieving higher imaging change score comparing higher catheter positioning
scores (= 2) vs. lower catheter positioning scores (0 or 1)
OR odds ratio, C.I. conﬁdence interval
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123fewer than two optimally positioned catheters (n = 70).
Figure 1 depicts the Kaplan–Meier Curves for OS and PFS
by catheter score. We further restricted the analysis to
include only patients with ideal overall placement (fully
conforming) and two or more optimal catheter positioning
scores. Among these 45 patients, the median OS was
38.1 weeks (95% CI, 30.9–49.4) and median PFS was
18.6 weeks (95% CI, 15.6–25.3). The median OS is con-
siderably less than that reported by Kunwar et al. among
patients who had two or more optimally positioned cathe-
ters. In the analysis from Sampson et al. the deﬁnition of
good catheter scores was slightly different including also
scores of 1. The authors found a signiﬁcant effect on PFS
after adjusting for KPS and age in patients with two or
more catheters with a good positioning score. No effect
was found on OS, which is in concordance with our ﬁnd-
ings. However, in this analysis we were unable to ﬁnd a
signiﬁcant effect on PFS, which was not a designated
endpoint in the PRECISE trial and therefore no central
review was performed [17].
The imaging change score had no effect on OS or PFS in
the Cox PH analysis after adjusting for age and KPS (OS:
P = 0.88 on day 43 and P = 0.20 on day 71; PFS:
P = 0.60 on day 43 MRI and P = 0.13 on day 71 MRI).
As expected, tumor control on day 43 was predictive of OS
(P = 0.01) and PFS (P = 0.001). However, we were
unable to detect a statistical signiﬁcant correlation on day
71 MRI possibly due to the smaller in sample size. Figure 2
Table 8 Cox proportional hazard model for PFS and OS
PFS OS
# pts # events HR (95% CI) P # pts # events HR (95% CI) P
Overall catheter placement
a 153 140 0.85 (0.61–1.20) 0.35 153 119 0.89 (0.62–1.29) 0.55
Catheter Positioning score
b 154 141 1.06 (0.76–1.48) 0.72 154 119 1.13 (0.78–1.63) 0.53
Image change score
c
Day 43
e 107 97 1.12 (0.73–1.71) 0.60 115 86 1.03 (0.67–1.60) 0.88
Day 71
f 75 66 1.53 (0.88–2.66) 0.13 96 72 1.39 (0.84–2.28) 0.20
Local tumor control
d
Day 43
e 107 97 0.44 (0.27–0.71) 0.001* 119 92 0.56 (0.35–0.88) 0.01*
Day 71
f 78 68 0.81 (0.43–1.52) 0.51 100 75 0.81 (0.48–1.38) 0.44
* Indicates signiﬁcant P-value
a Fully conﬁrming (all criteria fulﬁlled) vs. partially conﬁrming/non-conﬁrming
b Patients with C2 optimally placed catheters vs. patients with B1 optimally placed catheters
c Patients with C2 catheters graded with imaging change score 2 or above vs. patients with B1 catheter graded with imaging change score 2 or
above
d Patients with all catheters achieving local tumor control patients vs. patients with at least one catheter assessed as local tumor failure
e PFS analysis excluded patients who progressed by Day 43 and OS analysis excluded patients who died by Day 43
f PFS analysis excluded patients who progressed by Day 71 and OS analysis excluded patients who died by Day 71
Note: All hazard ratios (HR) represent the hazard of the clinical endpoint occurring (i.e. progression or death) comparing higher scores vs. lower
scores of the corresponding predictors. All P-values are associated with corresponding imaging variable after adjusting for age and KPS
Fig. 1 OS and PFS for patients
treated in the PRECISE study
with CB by CED by catheter
score
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by local tumor control status based on day 43 and day 71
MRI landmark analyses.
Discussion
The PRECISE trial is the largest study to date using CED
for the delivery of a genetically engineered therapeutic
agent for the treatment of patients with recurrent GBM.
The study did not meet its primary endpoint by not
showing a signiﬁcant OS difference between CB via CED
and GW. PFS was not a primary endpoint if this trial and
not centrally reviewed [12]. To further examine the
underlying reasons for this outcome, despite the very
promising phase I study results, we investigated imaging
characteristics on MRI scans obtained during this study.
We assessed catheter positioning scores, overall catheter
placement as well as imaging change scores for each MRI
scan obtained during the study and correlated the collected
variables with clinical outcome.
We found that 11% of patients did not fulﬁll the study
inclusion criteria of GTR deﬁned as greater than 95%
resection of the contrast-enhancing mass and only a small
percentage of patients (27%) had a complete (100%)
resection of their enhancing tumor based on our review of
the images. We excluded patients who did not fulﬁll the
inclusion criteria of GTR. Further, the deﬁnition of extent
of resection did not incorporate changes in T2/FLAIR
signal abnormality, which potentially characterize signiﬁ-
cant metabolic and/or tumor burden. As such, the degree of
variations in extent of resection may have inﬂuenced the
study outcome negatively [18].
Adetailedcatheterscoringsystemwasdevelopedpriorto
study initiationbased on studies using SPECT and
123I-HAS
(Plasbumin). These studies showed that using CED could
provideclinicallyrelevantintracerebraldistributionsofhigh
molecular weight compounds if catheters are accurately
placed [14]. The overall placement score was created to
determine placement in respect to resection cavity,
T2/FLAIR signal abnormality and other catheters, whereas
the catheter positioning score itself reﬂects the distance of
each catheter in relation to different brain surfaces. The
treating neurosurgeons underwent training for this complex
treatment plan and also received feedback after catheter
placement. Despite these speciﬁcations only 54% of the
catheters were fully conformed regarding their overall
placement and only 51% of all catheters were accurately
positioned. These numbers indicate that the use of CED as a
delivery technique is a highly specialized procedure and
implementation of strict procedures is required to ensure
accurateplacement.AnadhocanalysisofthePRECISEtrial
showed centers that enrolled more than six patients had a
higher median survival than centers that enrolled fewer
patients. More experience with catheter placement by the
treating neurosurgeon has been linked to improved survival
Fig. 2 Effect of local tumor on
day 43 and day 71 MRI on OS
and PFS. ? Indicates censored
observations. Note ‘‘Local
failure’’ represents subjects with
at least one local catheter
failure. ‘‘No local failure’’
represents subjects that
achieved local tumor control
in all catheters
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123[17].ThisindicatesthatthetrainingprovidedforCEDinthis
study may have been insufﬁcient and should be taken into
consideration when planning future trials. It might also be
beneﬁcial to restrict this kind of complex delivery technique
to centers of excellence to ensure the best possible outcome.
Further to bear in mind is that patients treated on the PRE-
CISE trial only received one infusion of the CB. If repeated
administration of the agent via CED would be surgically
feasible the beneﬁt on clinical outcome might be more
substantial than given the drug only once.
In this analysis, we found that local tumor control status
based on day 43 MRI was signiﬁcantly predictive of OS
and as expected of PFS. We were unable to establish this
relationship based on day 71 data potentially due to the
smaller sample size. Nevertheless, this ﬁnding is consistent
with the general belief of clinicians that delay in tumor
progression indicates the likelihood of prolonged survival.
In fact, a recent study based on the experience of the North
American Brain Tumor Consortium (NABTC) demon-
strates a strong correlation between progression status at
6 months and OS among adult patients with recurrent high
grade glioma [19].
Real time monitoring of drug distribution was not pro-
vided during the PRECISE study and we therefore used the
catheter positioning score and imaging change score as
surrogates. We were unable to ﬁnd any correlation between
catheter positioning score, local tumor control, and clinical
outcome. In a subset of patients treated on the PRECISE
trial, the distribution of the drug was estimated by using the
iPlan Flow software (BrainLab AG, Germany) [17]. The
authors found that there was a signiﬁcant correlation
between coverage volumes and overall catheter placement
score. However, no correlation was found between cover-
age volumes and PFS or OS [17]. Additionally, these
results are in contradiction to the analysis of prior phase I
studies, which showed that OS was linked to adequate
catheter placement. The median survival in the PRECISE
study for patients treated with CB was reported to be
45.3 weeks, which is in concordance with prior studies [9].
Conversely, the median survival for patients with good
catheter scores in the PRECISE trial was signiﬁcantly
lower (39.9 weeks with 95% CI, 32.6–52.4) compared to
prior phase I trials (55.6 weeks with 95% CI, 21.0–45.9).
In this analysis we used the same parameters to deﬁne good
catheter scores as that used in the phase I analysis (two or
more catheters with an optimal catheter positioning score
of 2). We further investigated if the overall placement
score affected these results. However, even patients with
good overall placement score and good catheter scores had
only a median survival of 38.1 weeks (95% CI, 30.9–
49.4 weeks). These results indicate that the catheter posi-
tioning score and overall placement score were not sufﬁ-
cient to predict response to therapy in the PRECISE trial.
Other techniques are needed to predict accurately the drug
distribution in vivo. Recently, gadoteridol-loaded lipo-
somes were shown to be successfully delivered in a canine
model via CED and this technology also allows for mon-
itoring of the distribution of these particles by real time
imaging [20]. Using this technique, a recent study from
Varenika et al. [21] showed that leakage occurred in 20%
of infusions in monkeys. The clinical development of such
a technique would identify patients in whom leakage
occurred during the infusion or who showed poor drug
distribution. Further trials using CED as a delivery method
should incorporate detailed analysis of drug distribution to
determine if delivery of the drug is adequate and covers the
expected area. Monitoring drug distribution will also help
to further identify additional factors needed to provide
adequate drug delivery, which is not currently captured in
the catheter positioning score or overall placement score.
Besides drug distribution, drug speciﬁcity and expres-
sion of the target molecule on tumor cells inﬂuence the
response to therapy. With respect to target expression,
several studies have shown that the target of CB, the
IL-13R, is over-expressed in a large number of high grade
glioma explants [6, 22]. A recent study using a commer-
cially available tissue array and IL-13R antibody showed
that up to 75% of patients with GBM over-express the
IL-13R. This will allow upfront testing for future trials and
should be included in the eligibility criteria [23]. The
percentage of IL13R positive samples within the PRECISE
cohort is currently not known and might have inﬂuenced
the outcome. Heterogeneous expression of the IL-13R has
been demonstrated in tumor samples as well as variation in
the expression from various sites of tumor, however the use
of different antibodies used in these studies makes it dif-
ﬁcult to assess the real impact of these ﬁndings [6, 22–25].
Given that most patients will undergo surgery at recur-
rence, the expression of the target gene at the tumor mar-
gins is much more crucial than the expression in the core of
the tumor. Further analysis of the expression of the IL-13R
in samples obtained during this trial will help to answer
some of these questions. In summary, more rigorous
upfront biological based inclusion criteria might be needed
when using a targeted therapy like CB.
CB related imaging changes seen during the PRECISE
trial were similar to what has been reported from phase I
studies. We used the imaging change score as a marker for
drug distribution based on a study that showed that new
FLAIR/T2 signal changes are correlated with drug distri-
bution [11]. We were unable to identify any correlation
between the imaging change score, local tumor control or
clinical outcome. The numbers of catheters associated with
more extensive imaging changes were relatively low and
therefore we might have lacked the statistical power to see
any differences.
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123Conclusion
The PRECISE study did not demonstrate a survival beneﬁt
of patients treated with CB versus GW in resectable
recurrent GBM. Despite intensive on site training a majority
of catheters were not positioned correctly highlighting the
complexity of this technique. Detailed analysis of catheter
positioning score, overall placement score and imaging
change score did not reveal any correlation of these
parameters with clinical outcome and better methods for
determining drug distribution by CED need to be included
in future study designs. Further analysis of the target
expression will be important to further identify areas of
improvement.
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